Eiger BioPharmaceuticals (NASDAQ: EIGR)
Some price data may be temporarily unavailable.
Eiger BioPharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Eiger BioPharmaceuticals Company Info
Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.
News & Analysis
Are Ultra-High Drug Prices Sustainable?
It depends on the ultimate cost to insurers.
Why Eiger BioPharmaceuticals Stock Skyrocketed Today
Investors were excited about the company's positive results from a COVID-19 clinical study
Why Eiger BioPharmaceuticals Stock Sank Today
The company reported disappointing news from a clinical study targeting COVID-19 outpatients.
2 Speculative Biotechs That Could Be Well Worth the Risk
Celladon Corp. and Exelixis Inc. are two speculative biotech stocks that might be worth their substantial risks.
Why Shares in Celladon Corp Burst Today
Celladon Corporation shares fell ahead of important trial data that is expected in April.
1 Clinical-Stage Biotech Stock That Could Make You Into a Millionaire
Celladon Corp. is nearing a make or break moment in its history with the release of its CUPID-2 top-line data for the cardiovascular gene therapy Mydicar. Here's why this speculative biotech is worth a deeper look by risk-tolerant investors.
Could This Clinical-Stage Biotech Stock Soar in April?
After 20 years of painstaking work, a game-changing cardiovascular treatment could soon be on hand, potentially richly rewarding early investors. Here's what you need to know.
Which Biotech Stock Should Pfizer, Inc. Buy?
Motley Fool contributors offer up three potential acquisition targets for Pfizer.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.